Leptin and Ghrelin in ICU

NCT ID: NCT02282501

Last Updated: 2016-03-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Enteral alimentation is the preferred modality of support in critical patients who have acceptable digestive function and are unable to eat orally, but the advantages of continuous versus intermittent administration are surrounded by controversy.

This prospective, randomised study was designed to compare two enteral feeding methods with respect to changes in levels of leptin and ghrelin in ICU.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critically Ill

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intermittent feeding

Bolus infusion - The total daily feeding period was also 4-6 times a day.

Group Type ACTIVE_COMPARATOR

enteral feeding by nasogastric tube.

Intervention Type OTHER

method of administration enteral feeding by nasogastric tube.

continuous feeding

Continuous infusion - The daily desired amount was offered continuously for 20 hours a day.

Group Type ACTIVE_COMPARATOR

enteral feeding by nasogastric tube.

Intervention Type OTHER

method of administration enteral feeding by nasogastric tube.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

enteral feeding by nasogastric tube.

method of administration enteral feeding by nasogastric tube.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* who were unable to ingest an oral diet
* given decision on enteral feeding

Exclusion Criteria

* Carcinomatosis
* irreversible coma
* death or discharge before 14 days of observation
* contraindication to enteral feeding
* intolerance to the prescribed nutrients or infusion regimen
* burn
* multiple trauma
* morbid obesity
* end stage liver or renal or lung disease
* severe sepsis or septic shock
* patients with percutaneous endoscopic gastrostomy
* immunosuppressive drug use
* severe hemodynamic instability
* massive blood transfusion
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

özgür yağan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

özgür yağan

MD, assistant professor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anesthesiology and Reanimation Dept. Ordu University Training and Research Hospital

Altinordu, Ordu, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Odu-4

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.